- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Companies join forces to market laser in Europe
Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.
Rotterdam, Netherlands, and Orlando-Topcon Europe Medical BV will distribute and market the LensAR Inc. product line (including a laser) in Europe under the terms of an agreement between the two companies. They expect commercial sales to start on the continent in the first quarter of next year.
“This is a very exciting opportunity for Topcon to significantly broaden our activities in ocular surgery,” said Eric Franken, managing director of Topcon Europe Medical BV. “We are well-known for our strengths in ocular diagnostics, and now we intend to use our strong direct sales presence in Europe to market the LensAR laser system to the benefit of our customers and their patients.”
Randy Frey, president and chief executive officer LensAR Inc., said: “We are very pleased to join forces with such a strong strategic partner. Topcon . . . is ideally positioned to market [the] . . . laser system in the European market.”
The laser system is cleared by the FDA for anterior capsulotomy and lens fragmentation. For other indications, it is an investigational device in the United States. To date, the system has been used in more than 500 eyes outside of the United States.
For more articles in this issue of
Ophthalmology Times Conference Brief
click here
.
